交易所数据显示，11月24日，冠昊生物收盘15.29元，上涨5.38%，滚动市盈率PE（当前股价与前四季度 每股收益总和的比值）达到154.16倍，总市值40.54亿元。 最新一期业绩显示，2025年三季报，公司实现营业收入2.93亿元，同比增加5.52%；净利润2671.85万 元，同比减少4.02%，销售毛利率77.69%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13冠昊生物154.16147.877.0940.54亿行业平均 52.1952.084.44109.78亿行业中值40.1437.372.7954.98亿1九安医疗10.2111.560.87192.85亿2康德莱 15.2317.241.3937.13亿3英科医疗15.4517.951.45263.10亿4奥美医疗15.5519.081.8970.36亿5维力医疗 15.7817.571.9938.56亿6安杰思17.2416.041.8947.05亿7新华医疗17.7313.041.1490.21亿8山东药玻 17.7414.391.67135.71亿9奥泰生物17.7717.311.3452.37亿10九强生物18.171 ...

（文章来源：证券日报） 证券日报网讯冠昊生物11月24日在互动平台回答投资者提问时表示，截至2025年11月20日，公司股东总 户数为29645户。 ...

Core Viewpoint - Guanhao Biological has shown a mixed performance in stock price, with a year-to-date increase of 23.26% but a recent decline over the past five, twenty, and sixty days [1][2]. Company Overview - Guanhao Biological Technology Co., Ltd. was established on October 22, 1999, and listed on July 6, 2011. The company is located in Huangpu District, Guangzhou, Guangdong Province [1]. - The main business involves research, production, and sales of regenerative medical materials and implantable medical devices, as well as cell therapy technology development, preparation, clinical application, and immune cell storage [1]. - The revenue composition is as follows: medical devices 73.28%, pharmaceuticals 15.21%, and leasing and other services 11.51% [1]. Financial Performance - For the period from January to September 2025, Guanhao Biological achieved an operating income of 293 million yuan, representing a year-on-year growth of 5.52%. However, the net profit attributable to the parent company was 26.72 million yuan, a decrease of 4.02% year-on-year [2]. - The company has cumulatively distributed 86.66 million yuan since its A-share listing, with no distributions in the past three years [3]. Shareholder Information - As of November 10, 2025, the number of shareholders for Guanhao Biological was 29,600, an increase of 4.20% from the previous period. The average circulating shares per person decreased by 4.03% to 8,951 shares [2]. - The top ten circulating shareholders include a new entrant, the Medical Device ETF (159883), holding 1.31 million shares [3]. Market Activity - On November 24, the stock price increased by 2.27% to 14.84 yuan per share, with a trading volume of 9.44 million yuan and a turnover rate of 0.24%. The total market capitalization is 3.935 billion yuan [1]. - The net inflow of main funds was 856,700 yuan, with large orders accounting for 11.99% of total purchases [1].

（编辑 袁冠琳） 证券日报网讯 冠昊生物11月17日在互动平台回答投资者提问时表示，安润®可降解泪小管栓是公司子公 司聚明生物自主研发的新一代干眼治疗产品，适用于角膜屈光、白内障等手术源性干眼的临时性泪道封 闭治疗。目前业务处于起步阶段，未来经营情况存在一定的不确定性，请投资者理性投资，注意风险。 公司将积极把握市场机遇，提升产品竞争力。公司产品研发方面的进展以及市场竞争力详情敬请关注公 司定期报告。 ...

证券日报网讯 冠昊生物（300238）11月17日在互动平台回答投资者提问时表示，安润 可降解泪小管栓 是公司子公司聚明生物自主研发的新一代干眼治疗产品，适用于角膜屈光、白内障等手术源性干眼的临 时性泪道封闭治疗。目前业务处于起步阶段，未来经营情况存在一定的不确定性，请投资者理性投资， 注意风险。公司将积极把握市场机遇，提升产品竞争力。公司产品研发方面的进展以及市场竞争力详情 敬请关注公司定期报告。 ...

Core Viewpoint - The company is actively developing a new generation of dry eye treatment products, specifically the Anrun® biodegradable tear duct plug, which is designed for temporary tear duct occlusion in patients undergoing corneal refractive surgery and cataract surgery. The market potential for this product is currently being assessed as the business is in its early stages, indicating some uncertainty in future operations [2]. Group 1 - The Anrun® biodegradable tear duct plug is a product developed by the company's subsidiary, Juming Biotechnology [2]. - The product targets temporary tear duct occlusion treatment for patients with surgery-induced dry eye conditions [2]. - The company acknowledges that its business is in the initial phase, which brings a level of uncertainty regarding future operational performance [2]. Group 2 - The company aims to seize market opportunities and enhance product competitiveness moving forward [2].

证券日报网讯冠昊生物（300238）11月13日在互动平台回答投资者提问时表示，截至2025年11月10日， 公司股东总户数为29620户。 ...

Core Insights - The medical device sector experienced a rise of 0.57% on November 12, with Tianyi Medical leading the gains [1] - The Shanghai Composite Index closed at 4000.14, down 0.07%, while the Shenzhen Component Index closed at 13240.62, down 0.36% [1] Medical Device Sector Performance - Tianyi Medical (301097) closed at 65.30, up 11.34% with a trading volume of 46,500 and a transaction value of 294 million [1] - Jimin Health (603222) closed at 11.33, up 10.00% with a trading volume of 729,500 and a transaction value of 797 million [1] - Zhongyuan Xiehe (600645) closed at 28.61, up 10.00% with a trading volume of 311,400 and a transaction value of 857 million [1] - Other notable gainers include Danah Biotechnology (920009) up 9.99%, Lideman (300289) up 9.89%, and Yipeng Medical (300753) up 8.21% [1] Capital Flow Analysis - The medical device sector saw a net inflow of 739 million from institutional investors, while retail investors experienced a net outflow of 923 million [2][3] - Jimin Health had a net inflow of 205 million from institutional investors, but a net outflow of 138 million from retail investors [3] - Zhongyuan Xiehe also saw a net inflow of 194 million from institutional investors, with a significant net outflow of 932 million from retail investors [3]

Group 1 - The immunotherapy sector is experiencing a strong rebound, with companies like Zhongyuan Qihuo and Kaineng Health hitting the daily limit up [1] - Other companies in the sector, such as Jimin Health, Guanhao Bio, Chengda Pharmaceutical, Zexing Pharmaceutical, and Heyuan Bio, are also showing significant gains [1]

资料显示，冠昊生物科技股份有限公司位于广东省广州市黄埔区玉岩路12号，成立日期1999年10月22 日，上市日期2011年7月6日，公司主营业务涉及再生医学材料及再生型医用植入器械研发、生产和销 售,以及细胞治疗技术研发、制备、临床应用,免疫细胞存储等。主营业务收入构成为：医疗器械 73.28%，药品15.21%，租赁及其他服务业11.51%。 从冠昊生物十大流通股东角度 11月12日，冠昊生物涨5.78%，截至发稿，报16.85元/股，成交1.93亿元，换手率4.45%，总市值44.68亿 元。 数据显示，永赢基金旗下1只基金位居冠昊生物十大流通股东。医疗器械ETF（159883）三季度新进十 大流通股东，持有股数131.28万股，占流通股的比例为0.5%。根据测算，今日浮盈赚取约120.78万元。 医疗器械ETF（159883）成立日期2021年4月22日，最新规模47.3亿。今年以来收益9.53%，同类排名 3722/4216；近一年亏损1.36%，同类排名3671/3937；成立以来亏损46.89%。 医疗器械ETF（159883）基金经理为储可凡。 截至发稿，储可凡累计任职时间2年92天，现任基金资 ...